References
- Rea J N, Newhouse M L, Halil T. Skin disease in Lambeth. A community study of prevalence and use of medical care. Br J Prev Soc Med 1976; 30: 107–14
- O'Neill P, Kelly P. Postal questionnaire study of disability in the community associated with psoriasis. BMJ 1996; 313: 919–21
- Koo J. Population-based epidemiological study of psoriasis with emphasis in quality of life assessment. Dermatol Clin 1996; 14: 485–96
- Feldman S R, Fleischer A B, Reboussin D M, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37: 564–9
- Cork M. Economic considerations in the treatment of psoriasis. Dermatol Tract 1993; 1: 16–20
- Wall A R, Poyner T F, Menday A P. Comparison of dithra-nol and calcipotriol for improving clinical severity and quality of life in treatment of psoriasis. Br J Dermatol 1998; 139: 1005–11
- Monthly Index of Medical Specialities. Haymarket Medical, London April, 1993
- Government Expenditure Plans 1996–7 to 1998–9, Department of Health. HMSO, LondonUK 1996
- The HFMA/CIPFA health database. Chartered Institute of Public Finance and Accountancy and Health Care Financial Management Association. 1994
- Conover W J. Practical non-parametric statistics, 2nd edn. J Wiley & Sons, New York 1980; 223–5
- Berth-Jones J, Chu A C, Dodd, et al. A multicentre parallel group comparison of calcipotriol ointment and short contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992; 127: 266–71